Genmab A/S (GMAB.CO) Stock Analysis & Winston Score

Genmab is a Danish biotechnology company that creates antibody-based medicines to treat cancer and other serious diseases. Its most important products include Darzalex (for blood cancer), which it developed with Johnson & Johnson, and Epkinly, a newer cancer treatment. Genmab specializes in building antibodies — proteins that can target and attack diseased cells — and partners with large pharmaceutical companies to develop and sell those medicines globally. Genmab makes money mainly through royalties and milestone payments when its partners sell drugs based on Genmab's antibody technology, plus direct product revenues from its own commercialized treatments. The company is headquartered in Copenhagen but operates internationally, with significant research presence in the Netherlands and the United States. Its core competitive advantage is its proprietary antibody technology platforms, which attract major pharma partners. The key risk is heavy revenue dependence on Darzalex royalties, meaning any slowdown in that drug's sales — or loss of patent protection — could significantly hurt the business.